Meibomian gland dysfunction
Conditions
Interventions
Group A:Topical 0.2% hyaluronic acid + 2% ectoin eye drops (Hylo Dual Intense, HI)
Group B:HI eye drops and nocturnal Vitamin A ointment (Hylo Night, HN)
Group C:HI eye drops and nocturnal HN ointment plus Optiben (OB) lid wipe
Sponsors
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Post-COVID infection patients; 2. Ocular surface disease index (OSDI) >= 13; 3. Non-invasive tear break up time = grade 2 in one eyelid; 5. >= 18 years of age with no upper age limit; 6. Agree to attend follow-up visits and comply to treatment regimen.
Exclusion criteria
Exclusion criteria: 1. Patients with drug allergy history or allergic constitution; 2. Allergy to lid wipe; 3. Contact lens wear 3 months before or during the study period; 4. Use of topical (including anti-glaucomatous, cyclosporin, antibiotics) or systemic medication known to affect (worsen or improve) MGD 3 months before or during the study period; 5. Major systemic (e.g. Sjogrens syndrome), dermatologic (e.g. Rosacea) known to affect MGD or ocular conditions (including thyroid eye disease, recurrent conjunctivitis, ocular allergies); 6. Ocular procedures (excluding uncomplicated cataract operation) 3 months before and any ocular procedure during the study period; 7. Women who are pregnant, nursing, planning pregnancy, or of childbearing potential not using a reliable method of contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline Tear film breakup time (TFBUT); | — |
Countries
China
Contacts
Public ContactDr Chong Kam Lung Kelvin
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Outcome results
None listed